Methods: This study assessed whether OBP-801, a novel HDAC inhibitor, affects the expression of immunoproteasome subunits and subsequently the MHC class-I-mediated anti-cancer immunity in ccRCC. The gene discussed is HDAC9; the disease is nonpapillary renal cell carcinoma.